Received Mar 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | — |
coronary artery occlusion; internuclear ophthalmoplegia; Covid-19 spike protein levels from 3385 arbitrary units per milliliter (AU/ml) at presentation to 2699 AU/ml; This spontaneous case was reported by a non-health professional and describes the occurrence of CORONARY ARTERY OCCLUSION (coronary artery occlusion) and OPHTHALMOPLEGIA (internuclear ophthalmoplegia) in a patient of an unknown age and gender who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below. No Medical History information was reported. On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (unknown route) 1 dosage form. On an unknown date, the patient experienced CORONARY ARTERY OCCLUSION (coronary artery occlusion) (seriousness criterion medically significant), OPHTHALMOPLEGIA (internuclear ophthalmoplegia) (seriousness criterion medically significant) and COVID-19 (Covid-19 spike protein levels from 3385 arbitrary units per milliliter (AU/ml) at presentation to 2699 AU/ml). The patient was treated with Ivermectin at a dose of more than 4 months. At the time of the report, CORONARY ARTERY OCCLUSION (coronary artery occlusion), OPHTHALMOPLEGIA (internuclear ophthalmoplegia) and COVID-19 (Covid-19 spike protein levels from 3385 arbitrary units per milliliter (AU/ml) at presentation to 2699 AU/ml) was resolving. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: 3385 arbitrary unit per millilitre and 2699 arbitrary unit per millilitre. The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Unknown) was unknown. Concomitant medication was not reported. It was reported that, patient had coronary artery occlusion and internuclear ophthalmoplegia after administration of Moderna COVID-19 mRNA vaccine. Administration of Ivermectin for more than four months led to notable improvements in the patient's symptoms, with a documented reduction in COVID-19 spike protein levels from 3385 arbitrary units per milliliter (AU/ml) at presentation to 2699 AU/ml. Most recent FOLLOW-UP information incorporated above includes: On 11-Mar-2025: Live non-significant follow-up was received. Reference ID was added.; Reporter's Comments: Concurrent COVID-19 might be a confounder given that Coronary artery occlusion and Ophthalmoplegia are complications that have been observed in patients who experienced this infection. The benefit-risk relationship of the product is not affected by this report.
Test Name: Covid-19 spike protein levels; Test Name: Covid-19 spike protein levels